Alexander Shulgin Research List

A list of journal articles by chemist Alexander Shulgin.

Shulgin, A. T., S. Bunnell, and T. Sargent. 1961. The psychotomimetic properties of 3,4,5-trimethoxyamphetamine. Nature 189: 10011-1012. 12 .XP

_____. 1963. Psychotomimetic agents related to mescaline. Experientia 19: 127. 19 .XP

_____. 1963. Composition of the myristicin fraction from oil of nutmeg. Nature 197: 379. 20 .XP

_____. 1963. Concerning the pharmacology of nutmeg. Mind 1: 299-302. 23 .XP

_____. 1964. 3-methoxy-4,5-methylenedioxy amphetamine, a new psychotomimetic agent. Nature 201: 1120-1121. 29 .XP

_____. 1964. Psychotomimetic amphetamines: methoxy 3,4-dialkoxyamphetamines. Experientia 20: 366. 30 .XP

_____, and H. O. Kerlinger. 1964. Isolation of methoxyeugenol and trans- isoelemicin from oil of nutmeg. Naturwissenschaften 15: 360-361. 31 .XP

_____. 1965. Synthesis of the trimethoxyphenylpropenes. Can. J. Chem. 43: 3437-3440. 43 .XP

_____. 1966. Possible implication of myristicin as a psychotropic substance. Nature 210: 380-384. 45 .XP

_____. 1966. The six trimethoxyphenylisopropylamines (trimethoxyamphetamines). J. Med. Chem. 9: 445-446. 46 .XP

_____, T. Sargent, and C. Naranjo. 1966. Role of 3,4-dimethoxyphenethylamine in schizophrenia. Nature 212: 1606-1607. 48 .XP

_____, T. Sargent, and C. Naranjo. 1967. The chemistry and psychopharmacology of nutmeg and of several related phenylisopropylamines. \fIIn\fR D. H. Efron [ed.]: Ethnopharmacologic search for psychoactive drugs. U. S. Dept. of H. E. W., Public Health Service Publication No. 1645. Pp. 202-214. Discussion: ibid. pp. 223-229. 49 .XP

_____, and T. Sargent. 1967. Psychotropic phenylisopropylamines derived from apiole and dillapiole. Nature 215: 1494-1495. 50 .XP

Sargent, T. W., D. M. Israelstam, A. T. Shulgin, S. A. Landaw, and N. N. Finley. 1967. A note concerning the fate of the 4-methoxyl group in 3,4-dimethoxyphenethylamine (DMPEA). Biochem. Biophys. Res. Commun. 29: 126-130. 52 .XP

Naranjo, C., A. T. Shulgin, and T. Sargent. 1967. Evaluation of 3,4-methylenedioxyamphetamine (MDA) as an adjunct to psychotherapy. Med. Pharmacol. Exp. 17: 359-364. 53 .XP

Shulgin, A. T. 1968. The ethyl homologs of 2,4,5-trimethoxyphenylisopropyl- amine. J. Med. Chem. 11: 186-187. 54 .XP

_____, T. Sargent, and C. Naranjo. 1969. Structure activity relationships of one-ring psychotomimetics. Nature 221: 537-541. 57 .XP

_____. 1969. Recent developments in cannabis chemistry. J. Psyched. Drugs 2: 15-29. 58 .XP

_____. 1969. Psychotomimetic agents related to the catecholamines. J. Psyched. Drugs 2(2): 12-26. 59 .XP

_____. 1970. Chemistry and structure-activity relationships of the psychotomimetics. \fIIn\fR: D. H. Efron [ed.]. Psychotomimetic Drugs. Raven Press, New York. Pp. 21-41. 60 .XP

_____. 1970. The mode of action of psychotomimetic drugs; some qualitative properties of the psychotomimetics. Neur. Res. Prog. Bull. 8: 72-78. 61 .XP

_____. 1970. 4-alkyl-dialkoxy-\fGa\fR-methyl-phenethylamines and their pharmacologically-acceptable salts. U. S. Patent 3,547,999, issued Dec. 15, 1970. 63 .XP

_____, T. Sargent, and C. Naranjo. 1971. 4-bromo-2,5-dimethoxyphenyliso- propylamine, a new centrally active amphetamine analog. Pharmacology 5: 103-107. 64 .XP

_____. 1971. Chemistry and sources. \fIIn\fR: S. S. Epstein [ed]. Drugs of abuse: their genetic and other chronic nonpsychiatric hazards. The MIT Press, Cambridge, Mass. Pp 3-26. 65 .XP

_____. 1971. Preliminary studies of the synthesis of nitrogen analogs of \fGD\fR\u\s-21\s+2\d-THC. Acta Pharm. Suec. 8: 680-681. 66 .XP

_____. 1972. Hallucinogens, CNS stimulants, and cannabis. \fIIn\fR: S. J. Mule/*' and H. Brill [eds.]: Chemical and biological aspects of drug dependence. CRC Press, Cleveland, Ohio. Pp. 163-175. 67 .XP

_____. 1973. Stereospecific requirements for hallucinogenesis. J. Pharm. Pharmac. 25: 271-272. 68 .XP

_____. 1973. Mescaline: the chemistry and pharmacology of its analogs. Lloydia 36: 46-58. 69 .XP

_____. 1973. The narcotic pepper - the chemistry and pharmacology of \fIPiper methysticum\fR and related species. Bull. Narc. 25: 59-74. Le poivre stupe\*'fiant - chemie et pharmacologie du \fIPiper methysticum\fR et des espe\*'ces apparente\*'es. Bull. Stupe\*'fiants 25: 61-77. 70 .XP

_____, T. Sargent, and C. Naranjo. 1973. Animal pharmacology and human psychopharmacology of 3-methoxy-4,5-methylenedioxyphenylisopropylamine (MMDA). Pharmacology 10: 12-18. 71 .XP

_____. Drugs of abuse in the future. Drug abuse in America Vol. 1. pp. 209-236. U.S.G.P.O. 5266-00004. Reprinted: Clin. Tox. 8: 405-456. 72 .XP

Kalbhen, D. A., T. Sargent, A. T. Shulgin, G. Braun, H. Stauffer, N. Kusubov, and M. L. Nohr. 1974. Human pharmacodynamics of the psychodysleptic 4-bromo-2,5-dimethoxyphenylisopropylamine labelled with \u82\dBr. IRCS (Int. Res. Comm. Sys.) 2: 1091. 73 .XP

Sargent, T., D. A. Kalbhen, A. T. Shulgin, H. Stauffer, and N. Kusubov. 1975. A potential new brain-scanning agent: 4-\u77\dBr-2,5-dimethoxyphenyliso- propylamine (4-Br-DPIA). J. Nucl. Med. 16: 243-245. 74 .XP

Shulgin, A. T., and M. F. Carter. 1975. Centrally active phenethylamines. Psychopharm. Commun. 1: 93-98. 75 .XP

Sargent, T., D. A. Kalbhen, A. T. Shulgin, G. Braun, H. Stauffer, and N. Kusubov. 1975. \fIIn vivo\fR human pharmacodynamics of the psychodysleptic 4-Br-2,5-dimethoxyphenylisopropylamine labelled with \u82\dBr or \u77\dBr. Neuropharmacology 14: 165-174. 76 .XP

_____. 1975. The chemical catalysis of altered states of consciousness. Altered states of consciousness, current views and research problems. The drug abuse council, Washington, D. C. Pp. 123-134. 77 .XP

_____. 1975. Drug use and anti-drug legislation. The PharmChem Newsletter 4 (#8). 79 .XP

_____, and D. C. Dyer. 1975. Psychotomimetic phenylisopropylamines. 5. 4-alkyl-2,5-dimethoxyphenylisopropylamines. J. Med. Chem. 18: 1201-1204. 80 .XP

_____, and C. Helisten. 1975. Differentiation of PCP, TCP, and a contaminating precursor PCC, by thin layer chromatography. Microgram 8: 171-172. 81 .XP

Helisten, C., and A. T. Shulgin. The detection of 1-piperidinodydlohexane- carbonitrile contamination in illicit preparations of 1-(1-phenylcyclohexyl) piperidine and 1-(1-(2-thienyl)cyclohexyl)piperidine. J. Chrom. 117: 232-235. 82 .XP

Shulgin, A. T. 1976. Psychotomimetic agents. \fIIn\fR: M. Gordon [ed.] Psychopharmacological agents, Vol. 4. Academic Press, New York. Pp. 59-146. 83 .XP

_____. 1976. Abuse of the term "amphetamines". Clin. Tox. 9: 351-352. 84 .XP

_____. 1976. Profiles of psychedelic drugs. 1. DMT. J. Psychedelic Drugs 8: 167-168. 85 .XP

_____. 1976. Profiles of psychedelic drugs. 2. TMA-2. J. Psychedelic Drugs 8: 169. 86 .XP

_____, and D. E. MacLean. 1976. Illicit synthesis of phencyclidine (PCP) and several of its analogs. Clin. Tox. 9: 553-560. 87 .XP

Nichols, D. E., and A. T. Shulgin. 1976. Sulfur analogs of psychotomimetic amines. J. Pharm. Sci. 65: 1554-1556. 89 .XP

Sargent, T., A. T. Shulgin, and N. Kusubov. 1976. Quantitative measurement of demethylation of \u14\dC-methoxyl labeled DMPEA and TMA-2 in rats. Psychopharm. Commun. 2: 199-206. 90 .XP

Standridge, R. T., H. G. Howell, J. A. Gylys, R. A. Partyka, and A. T. Shulgin. 1976. Phenylalkylamines with potential psychotherapeutic utility. 1. 2-amino-1-(2,5,-dimethoxy-4-methylphenyl)butane. J. Med. Chem. 19: 1400-1404. 91 .XP

_____. 1976. Profiles of psychedelic drugs. 3. MMDA. J. Psychedelic Drugs 8: 331. 92 .XP

_____. 1977. Profiles of psychedelic drugs. 4. Harmaline. J. Psychedelic Drugs 9: 79-80. 93 .XP

_____. 1977. Profiles of psychedelic drugs. 5. STP. J. Psychedelic Drugs. 9: 171-172. 94 .XP

Nichols, D. E., A. T. Shulgin, and D. C. Dyer. 1977. Directional lipophilic character in a series of psychotomimetic phenethylamine derivatives. Life Sciences 21: 569-576. 95 .XP

Jacob, P. III, G. Anderson III, C. K. Meshul, A. T. Shulgin, and N. Castagnoli Jr. 1977. Mononethylthio analogues of 1-(2,4,5-trimethoxyphenyl)- 2-aminopropane. J. Med. Chem. 20: 1235-1239. 96 .XP

White, T. J., D. Goodman, A. T. Shulgin, N. Castagnoli Jr., R. Lee, and N. L. Petrakis. 1977. Mutagenic activity of some centrally active aromatic amines in \fISalmonella typhimurium\fR. Mutation Research 56: 199-202. 97 .XP

Braun, U., A. T. Shulgin, G. Braun, and T. Sargent III. 1977. Synthesis and body distribution of several iodine-131 labeled centrally acting drugs. J. Med. Chem. 20: 1543-1546. 98 .XP

Sargent, T. III, T. F. Budinger, G. Braun, A. T. Shulgin, and U. Braun. 1978. An iodated catecholamine congener for brain imaging and metabolic studies. J. Nucl. Med. 19: 71-76. 99 .XP

Shulgin, A. T. 1978. Psychotomimetic drugs: structure-activity relationships. \fIIn\fR: L. L. Iversen, S. D. Iversen, and S. H. Snyder [eds.], Handbook of psychopharmacology, Vol. 11. Plenum Press, New York. Pp. 243-333. .XP

Sargent, T. III, G. Braun, U. Braun, T. F. Budinger, and A. T. Shulgin. 1978. Brain and retina uptake of a radio-iodine labeled psychotomimetic in dog and monkey. Commun. Psychopharm. 2: 1-10. 101 .XP

Braun, G., A. T. Shulgin, and T. Sargent III. 1978. Synthesis of \u123\dI-labelled 4-iodo-2,5-dimethoxyphenylisopropylamine. J. Labelled Comp. and Radiopharm. 14: 767-773. 102 .XP

Murdock, J. E., J. R. Patty, and A. T. Shulgin. 1978. A novel illicit amphetamine laboratory. Microgram 11: 98-101. 103 .XP

Anderson, G. M. III, G. Braun, U. Braun, D. E. Nichols, and A. T. Shulgin. 1978. Absolute configuration and psychotomimetic activity. \fIIn\fR: G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22. N.I.D.A. Washington, D.C. Pp. 8-15. 104 .XP

Braun, U., G. Braun, P. Jacob III, D. E. Nichols, and A. T. Shulgin. Mescaline analogs: substitutions at the 4-position. \fIIn\fR: G. Barnett, M. Trsic, and R. Willette [eds.], QuaSAR Research Monograph 22. N.I.D.A. Washington, D.C. Pp. 27-37. 105 .XP

Partyka, R. A., R. T. Standridge, H. G. Howell, and A. T. Shulgin. 1978. 2-amino-1-(2,5-dimethoxyphenyl)butanes. U.S. Patent 4,105,695, issued Aug. 8, 1978. 106 .XP

Shulgin, A. T., and D. E. Nichols. 1978. Characterization of three new psychotomimetics. \fIIn\fR: R. C. Stillman and R. E. Willette [eds.], The psychopharmacology of hallucinogens. Pergamon Press, New York. Pp. 74-83. 107 .XP

Glennon, R. A., L. B. Kier, and A. T. Shulgin. 1979. Molecular connectivity analysis of hallucinogenic mescaline analogs. J. Pharm. Sci. 68: 906-907. 108 .XP

Shulgin, A. T. 1979. Chemistry of phenethylamines related to mescaline. J. Psychedelic Drugs 11: 41-52. 109 .XP

_____. 1979. Profiles of psychedelic drugs. 6. \fGa\fR,O-DMS. J. Psychedelic Drugs 11: 247. 110 .XP

_____. 1979. Profiles of psychedelic drugs. 7. Mescaline. J. Psychedelic Drugs 11: 355. 111 .XP

Standridge, R. T., H. G. Howell, H. A. Tilson, J. H. Chamberlain, H. M. Holava, J. A. Gylys, R. A. Partyka, and A. T. Shulgin. 1980. Phenylalkylamines with potential psychotherapeutic utility. 2. Nuclear substituted 2-amino-1-phenylbutanes. J. Med. Chem. 23: 154-162. 112 .XP

Braun, U., A. T. Shulgin, and G. Braun. 1980. Centrally active N-substituted analogs of 3,4-methylenedioxyphenylisopropylamine (3,4-methylenedioxyamphetamine). J. Pharm. Sci. 69: 192-195. 113 .XP

Kantor, R. E., S. D. Dudlettes, and A. T. Shulgin. 1980. 5-methoxy- \fGa\fR-methyltryptamine (\fGa\fR,O-dimethylserotonine) a hallucinogenic homolog of serotonin. Biol. Psychiat. 15: 349-352. 114 .XP

Shulgin, A. T. 1980. Profiles of psychedelic drugs. 8. psilocybin. J. Psychedelic Drugs 12: 79. 115 .XP

Braun, U., A. T. Shulgin, and G. Braun. 1980. Pru\*:fung auf Aktivita\*:t und Analgesia von N-substituierten Analogen des Amphetamin- Derivates 3,4-Methylendioxyphenylisopropylamin. Arzneim. Forsch. 30: 825-830. 116 .XP

Shulgin, A. T. 1980. Profiles of psychedelic drugs. 9. LSD. J. Psychedelic Drugs 12: 173-174. 117 .XP

_____. 1981. Hallucinogens. \fIIn\fR: M. E. Wolff [ed.], Burger's medicinal chemistry. Wiley & Co. Pp. 1109-1137. .XP

_____. 1981. Profiles of psychedelic drugs. 10. DOB. J. Psychoactive Drugs 13: 99. 119 .XP

_____, and M. F. Carter. 1981. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol. 4: 363-369. 120 .XP

Jacob, P., and A. T. Shulgin. 1981. Sulfur analogues of psychotomimetic agents. Monothio analogues of mescaline and isomescaline. J. Med. Chem. 24: 1348. 121 .XP

Domelsmith, L. N., T. A. Eaton, K. N. Houk, G. M. Anderson, R. A. Glennon, A. T. Shulgin, N. Castagnoli, and P. A. Kollman. 1981. Photoelectron spectra of psychotropic drugs. 6. Relationships between physical properties and pharmacological actions of amphetamine analogues. J. Med. Chem. 24: 1414. 122 .XP

Shulgin, A. T. 1981. Chemistry of psychotomimetics. \fIIn\fR: F. Hoffmeister and G. Stille [eds.], Handbook of experimental pharmacology, Vol. 55/III. Springer-Verlag, Berlin Heidelberg. Pp. 3-29. .XP

_____. 1981. Profiles of psychedelic drugs. 11. Bufotenine. J. Psychoactive Drugs 13: 389. 124 .XP

_____, and P. Jacob. 1982. Potential misrepresentation of 3,4-methylene- dioxyamphetamine (MDA). A toxicological warning. J. Anal. Tox. 6: 71. 127 .XP

_____, and P. Jacob. 1982. 1-(3,4-methylenedioxyphenyl)-3-aminobutane: a potential toxicological problem. J. Toxicol. - Clin. Toxicol. 19: 109. 128 .XP

Jacob, P., and A. T. Shulgin. 1983. Sulfur analogues of psychotomimetic agents. 2. Analogues of (2,5-dimethoxy-4-methylphenyl)- and (2,5- dimethoxy-4-ethylphenyl)-isopropylamine. J. Med. Chem. 26: 746. 130 .XP

Shulgin, A. T. 1983. Twenty years on an ever-changing quest. \fIIn\fR: L. Grinspoon and J. B. Bakalar [eds.], Psychedelic Reflections. Human Sciences Press, New York. 131 .XP

Sargent, T., A. T. Shulgin, and C. A. Mathis. 1982. New iodinated amphetamines by rapid synthesis for use as brain blood flow indicators. J. Lab. Cmpds. and Radiopharm. 19: 1307. 132 .XP

Jacob, P., and A. T. Shulgin. 1984. Sulfur analogues of psychotomimetic agents. 3. The ethyl homologues of mescaline and their monothio analogues. J. Med. Chem. 27: 881-888. 133 .XP

Sargent, T., A. T. Shulgin, and C. A. Mathis. 1984. Radiohalogen-labeled imaging agents. 3. Compounds for measurement of brain blood flow by emission tomography. J. Med. Chem. 27: 1071-1077. 135 .XP

Repke, D. B., D. B. Grotjahn, and A. T. Shulgin. 1985. Psychotomimetic N-methyl-N-isopropyltryptamines. Effects of variation of aromatic oxygen substituents. J. Med. Chem. 28: 892. 136 .XP

Shulgin, A. T. 1985. What is MDMA? PharmChem Newsletter 14: 3 (May-June, #3). 137 .XP

Lemaire, D., P. Jacob, and A. T. Shulgin. 1985. Ring substituted beta-methoxyphenethylamines: a new class of psychotomimetic agents active in man. J. Pharm. Pharmacol. 37: 575. 138 .XP

Mathis, C. A., T. Sargent, and A. T. Shulgin. 1985. Iodine-122 labeled amphetamine derivatives with potential for PET brain blood-flow studies. J. Nucl. Med. 26: 1295. 139 .XP

_____, _____, and _____. 1986. Synthesis of 122-I and 125-I-labeled- \fImeta\fR-dimethoxy-N,N-dimethyliodophenylisopropylamines. J. Labelled Comp. Radiopharm. 23: 115. 140 .XP

Shulgin, A. T., L. A. Shulgin, and P. Jacob. 1986. A protocol for the evaluation of new psychoactive drugs. Methods and Findings in Experimental and Clinical Pharmacology 8: 313. 141 .XP

Nichols, D. E., A. J. Hoffman, R. A. Oberlender, P. Jacob, and A. T. Shulgin. 1986. Derivatives of 1-(1,3-benzodioxol-5-yl)-2-butanamine: representatives of a novel therapeutic class. J. Med. Chem. 29: 2009. 143 .XP

Mathis, C. A., A. T. Shulgin, Y. Yano, and T. Sargent. 1986. \u18\dF- labelled N,N-dimethylamphetamine analogues for brain imaging studies. Appl. Radiat. Isot. 37: 865. 144 .XP

Shulgin, A. T. 1986. The background and chemistry of MDMA. J. Psychoactive Drugs 18: 291-304. 145 .XP

Sargent, T. W., A. T. Shulgin, and C. A. Mathis. 1987. Rapid brain scanning pharmaceutical. U. S. Patent 4,647,446. 146 .XP

McKenna, D. J., C. A. Mathis, A. T. Shulgin, T. Sargent, and J. M. Saavedra. 1987. Autoradiographic localization of binding sites for \u125\dI-DOI, a new psychotomimetic radioligand, in the rat brain. Eur. J. Pharmacol. 137: 289-290. 147 .XP

Shulgin, A. T. 1987. The 'social-chemistry' of pharmacological discovery. Social Pharmacology 1: 279-290. 148 .XP

_____. 1987. Reference information on MDMA. Analog 9: #4 (page 10). 149 .XP

_____. 1988. DIPT: the distortion of music. Reality Hackers #6 (Winter 1988) p. 27. 152. .XP

_____. 1988. THE CONTROLLED SUBSTANCES ACT: A resource manual of the current status of the federal drug laws. 383 pp., published in Lafayette, California 94549 April 1988. 154 .XP

_____. In press. History of MDMA. \fIIn\fR: S. Peroutka [ed.], MDMA: "Ecstasy" and human neurotoxin? Kluwer Academic Publishers, Norwell, MA,